Oncology Times, Nov. 25, 2007 An unprecedented number of cancer patients now survive in the United States. But long-term cardiac or pulmonary toxicity can be a problem for breast cancer patients who received anthracyclines, radiotherapy or trastuzumab. Two recent reports in the Journal of Clinical Oncology highlight the dangers of anthracyclines. One report, by researchers at the Department of Breast Medical Oncology at the University of Texas M. D. Anderson Cancer Center and the University of Texas Medical Branch at Galveston, evaluated the rates and predictors of congestive heart failure in women over age 65 who had received adjuvant anthracycline therapy.